このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Meridian Bioscience 将来の成長

Future 基準チェック /06

現在、 Meridian Bioscienceの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Medical Equipment 収益成長	16.7%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Aug 05

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Jun 09

Meridian Bioscience: Deceptively Priced

Mar 14

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Feb 03

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Jul 19

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Jul 08

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

May 10

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

May 08

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Mar 31

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Mar 11

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Feb 24

Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Feb 09

Meridian expands production capacity for COVID-19 tests with NIH funding

Feb 03

Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Jan 27

業績と収益の成長予測

NasdaqGS:VIVO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2023	288	35	N/A	N/A	2
9/30/2022	333	42	74	82	N/A
6/30/2022	344	43	88	95	N/A
3/31/2022	339	62	82	91	N/A
12/31/2021	313	60	59	77	N/A
9/30/2021	318	71	49	67	N/A
6/30/2021	306	71	51	69	N/A
3/31/2021	327	87	60	74	N/A
12/31/2020	299	70	63	68	N/A
9/30/2020	254	46	45	48	N/A
6/30/2020	240	44	36	39	N/A
3/31/2020	204	21	28	31	N/A
12/31/2019	197	19	29	32	N/A
9/30/2019	201	24	32	36	N/A
6/30/2019	203	26	36	40	N/A
3/31/2019	207	27	38	42	N/A
12/31/2018	213	26	35	39	N/A
9/30/2018	214	24	31	35	N/A
6/30/2018	210	24	28	32	N/A
3/31/2018	209	18	26	30	N/A
12/31/2017	206	22	29	34	N/A
9/30/2017	201	22	37	41	N/A
6/30/2017	198	21	39	44	N/A
3/31/2017	199	30	39	44	N/A
12/31/2016	195	30	34	38	N/A
9/30/2016	196	32	33	37	N/A
6/30/2016	195	35	N/A	38	N/A
3/31/2016	192	36	N/A	41	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VIVOの予測収益成長が貯蓄率 ( 2% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: VIVOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: VIVOの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: VIVOの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: VIVOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VIVOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Meridian Bioscience 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased to US$34.00

Consensus EPS estimates fall by 31%

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Price target increased to US$30.00

Recent updates

Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits

Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex

Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Independent Director exercised options to buy US$285k worth of stock.

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$34.00

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Consensus EPS estimates fall by 31%

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience: High-Probability Merger Arbitrage

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Meridian Bioscience downgraded at William Blair on $1.53B acquisition

Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index

Meridian Bioscience: Correctly Valued

President exercised options and sold US$1.1m worth of stock

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Insufficient new directors

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Meridian Bioscience: Deceptively Priced

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Investor sentiment improved over the past week

Price target increased to US$30.00

Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience, Inc. Announces Board Changes

Key Executive exercised options to buy US$157k worth of stock.

Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Insufficient new directors

Insufficient new directors

Price target decreased to US$27.00

Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Price target decreased to US$30.50

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix

Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Consensus forecasts updated

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020)

Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

Meridian Bioscience, Inc. Announces the Launch of the Lyo-Ready DNA LAMP Mix

Investor sentiment deteriorated over the past week

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

President recently sold US$250k worth of stock

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Meridian Bioscience, Inc. Announces the Launch of New Air-Dryable Direct DNA qPCR Blood Mix

Meridian Bioscience Provides A Further Update on the Revogene® Sars-Cov-2 Eua Submission

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides an Update on the Revogene SARS-CoV-2 EUA Submission